Cai HQ, Zhang LY, Fu LM, Xu B, Jiao Y. Mutational landscape of TP53 and CDH1 in gastric cancer. World J Gastrointest Surg 2024; 16(2): 276-283 [PMID: 38463349 DOI: 10.4240/wjgs.v16.i2.276]
Corresponding Author of This Article
Yan Jiao, MD, PhD, Adjunct Associate Professor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Feb 27, 2024; 16(2): 276-283 Published online Feb 27, 2024. doi: 10.4240/wjgs.v16.i2.276
Mutational landscape of TP53 and CDH1 in gastric cancer
Hong-Qiao Cai, Li-Yue Zhang, Li-Ming Fu, Bin Xu, Yan Jiao
Hong-Qiao Cai, Yan Jiao, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Li-Yue Zhang, Department of Critical Care Medicine, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Li-Ming Fu, Bin Xu, Department of Traditional Chinese Medicine, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China
Author contributions: Jiao Y designed the overall concept and outline of the manuscript; Cai HQ contributed to the discussion and design of the manuscript; Zhang LY, Fu LM, and Xu B contributed to the writing, and editing the manuscript, illustrations, and review of literature.
Supported bythe Youth Development Fund Task Book of the First Hospital of Jilin University, No. JDYY13202210.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Jiao, MD, PhD, Adjunct Associate Professor, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun 130021, Jilin Province, China. lagelangri1@126.com
Received: December 10, 2023 Peer-review started: December 10, 2023 First decision: December 18, 2023 Revised: December 26, 2023 Accepted: January 30, 2024 Article in press: January 30, 2024 Published online: February 27, 2024 Processing time: 77 Days and 13.8 Hours
Abstract
In this editorial we comment on an article published in a recent issue of the World J Gastrointest Surg. A common gene mutation in gastric cancer (GC) is the TP53 mutation. As a tumor suppressor gene, TP53 is implicated in more than half of all tumor occurrences. TP53 gene mutations in GC tissue may be related with clinical pathological aspects. The TP53 mutation arose late in the progression of GC and aided in the final switch to malignancy. CDH1 encodes E-cadherin, which is involved in cell-to-cell adhesion, epithelial structure maintenance, cell polarity, differentiation, and intracellular signaling pathway modulation. CDH1 mutations and functional loss can result in diffuse GC, and CDH1 mutations can serve as independent prognostic indicators for poor prognosis. GC patients can benefit from genetic counseling and testing for CDH1 mutations. Demethylation therapy may assist to postpone the onset and progression of GC. The investigation of TP53 and CDH1 gene mutations in GC allows for the investigation of the relationship between these two gene mutations, as well as providing some basis for evaluating the prognosis of GC patients.
Core Tip: The separation of TP53 and CDH1 mutations in gastric cancer (GC) demonstrates their separate processes. Mutations in TP53 are linked to advanced-stage cancers and a poor prognosis, whereas CDH1 mutations are linked to widespread GC. This work emphasizes the variability of GC and sheds light on prospective targeted therapeutics based on distinct mutation patterns. Understanding the mutational landscape of TP53 and CDH1 can help to develop tailored therapy strategies for GC patients.
